Adverse Events of Special Interest in Patients With Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study. J of Skin 2020, 4 (5), s67. https://doi.org/10.25251/skin.4.supp.66.